Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Access Control
10%
Adaptive Response
10%
Administration Time
10%
Cancer Therapy
100%
Clinical Model
10%
Cyclophosphamide
21%
Dose Timing
10%
Host Immune Response
10%
Immune-competent
10%
Immune-competent Host
21%
Mayo Clinic
10%
Metastatic Disease
21%
Metastatic Tumor
10%
Murine Tumors
10%
Neutralizing Antibodies
21%
New Trial
10%
Novel Protocols
10%
Oncolytic Virotherapy
10%
Oncolytic Virus
100%
Ongoing Trials
10%
Phase I Trial
10%
Physical Barrier
10%
Regulatory Agencies
10%
Reovirus
10%
Repeated Administration
10%
Specific Aims
10%
Systemic Agents
10%
Systemic Delivery
100%
Therapeutic Level
10%
Tumor
53%
Tumor Localization
21%
Tumor Vasculature
10%
Vascular Barrier
10%
Vascular Permeability
10%
Vesicular Stomatitis Virus
21%
Viral
21%
Virotherapy
10%
Virus
100%
Virus Survival
10%
Medicine and Dentistry
Adaptive Response
10%
Antivirus Agent
21%
Blood Vessel Permeability
10%
Cancer Therapy
100%
Clinical Trial
14%
Cyclophosphamide
21%
Extravasation
10%
Immune System
10%
Metastatic Carcinoma
32%
Neutralizing Antibody
21%
Oncolytic Virotherapy
10%
Oncolytic Virus
100%
Reoviridae
10%
Tumor
64%
Tumor Localization
21%
Tumor Vascularization
10%
Vesiculovirus
21%
Virotherapy
10%
Virus
100%
Virus Survival
10%
Pharmacology, Toxicology and Pharmaceutical Science
Antivirus Agent
19%
Clinical Trial
12%
Cyclophosphamide
19%
Extravasation
9%
Malignant Neoplasm
100%
Neoplasm
19%
Neutralizing Antibody
19%
Oncolytic Virus
100%
Reoviridae
9%
Tumor Vascularization
9%
Vesiculovirus
19%
Virotherapy
19%
Virus
100%